The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal

Thu, 10th Nov 2022 21:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Ace Liberty & Stone PLC - Edinburgh-based commercial property investment company - Exchanges contracts to acquire Loders Service Station, The Grove, Dorchester at a value of GBP2.1 million. The annual rental income is GBP167,914 which increases to GBP185,391 in 2028 and GBP204,697 in 2033, it says. "This acquisition further enhances our already strong portfolio, providing a long-term income stream which is very welcome in the current uncertain economic climate," Chief Executive Ismail Ghandour comments.

----------

hVIVO PLC - specialist contract research organisation - Signs a GBP13.6 million contract with an unnamed, US-based biopharmaceutical client to test its respiratory syncytial virus antiviral candidate. Expects the study to start in the third or fourth quarter of 2023, with revenue being recognised in 2023 and 2024. "We're delighted to be working with this biopharma client to test their antiviral candidate using our established hVIVO RSV Human Challenge Study Model. We continue to see an increase in the size of our studies as new benefits of challenge study data are continually realised by both new and existing biotech and pharma clients, " Chief Executive Yamin 'Mo' Khan comments.

----------

Guanajuato Silver Co Ltd - silver producer in Mexico - Confirms the discovery of a new transverse vein at its wholly owned El Cubo mine in Guanajuato, Mexico. Says the new vein structure has been named the San Luis vein. Says the extent of the mineralization remains unknown. "Economic success of our operations is driven by grade, and the identification of another gold-rich transverse vein that can rapidly enhance our mining schedule further demonstrates the considerable potential remaining at El Cubo. With almost 200 years of mining history behind it, El Cubo is ready to begin a new chapter of growth as the centerpiece of our hub & spoke strategy in Guanajuato," CEO & Chair James Anderson comments.

----------

Zambeef Products PLC - Zambia-focused cold chain foods and retail business - Expects revenue, adjusted earnings before interest, tax, depreciation, and amortisation and reported pretax profit for the year ended September 30 to be in line with current market expectations. Expects adjusted pretax profit to be roughly 10% ahead of expectations, due to higher-than-expected profit at assets held for sale and discontinued operations. Expects its full-year results to be released by the end of November 2022. "The period saw an escalation in key input prices such as fuel, chemicals, and fertiliser which impacted margins. In addition, the group saw outbreaks of contagious bovine pleuropneumonia and African swine fever, both of which were successfully managed, in line with government guidelines. Despite these headwinds, performance in Cropping, Milling, and Stockfeed enabled the group to achieve adjusted Ebitda in line with market expectations owing to high grain prices, market share gains, and cost containment," the company says.

----------

Mobile Streams PLC - London-based mobile content provider - Signs a 5-year contract to be the exclusive provider of non-fungible token trading cards, collectables and other agreed NFT products for Necaxa Football club. The companies target a revenue figure over the 5 years of the contract of which MOS's potential share is roughly USD 8.8 million. The revenue from the NFTs will come from both the sale price of the NFT itself, as well as royalty generated from them each time they are traded in perpetuity, these royalties are typically 5% to 10% of the sale price, it says. "We are delighted to have signed this contract. Necaxa are a hugely popular team with a great fan base. It's privilege to be working with such a great club. In addition I would like to thank their management team who have a great vision for the club," CEO Mark Epstein comments.

----------

Syncona Ltd - investor in healthcare companies - Says its ongoing phase I/II study of ANV419 in patients with solid tumours identified a favourable safety and tolerability profile of the drug. Further, it records "encouraging" efficacy data with 66% of patients achieving at least disease stabilisation at ANV419 doses greater than or equal to 108 micrograms per kilogram. "We are pleased to see the drug continue to present a strong safety and tolerability profile. Critically for patients, the data is showing deepening of tumour response with continued ANV419. We look forward to seeing further data from Anaveon as it initiates Phase I/II trials in metastatic melanoma and multiple myeloma and are excited by the potential of this drug to deliver for patients in real need," CEO Martin Murphy says.

----------

Kromek Group PLC - Sedgefield, England-based detection technology supplier - Says it has received and delivered a contract worth USD1.3 million from an unnamed US customer for its D3M wearable radiation detector. Altogether, it has delivered D3M orders worth USD2.6m to this customer in the last six months, as the contract is a repeat order, it explains. D3M is a high-performance combined gamma/neutron personal radiation detector.

----------

Belluscura PLC - A london-based medical device developer - Reports that it has been certified as compliant with ISO standards for quality management. This will allows for design, development, manufacture and distribution of its portable oxygen concentrator, following an extensive audit process undertaken by leading global assurance provider SGS. "This is a hugely significant step for the group, as ISO 13485 certification will enable the company to begin the process to start distributing its products globally. Our existing market in the US represents approximately 45% of the Portable Oxygen Concentrator market, so this certification more than doubles the available market opportunity for the group," Chief Executive Robert Rauker comments.

----------

European Metals Holdings Ltd - mineral exploration and development company - Says Marc Rowley will lead its definitive feasibility study team to progress the Cinovec project in the Czech Republic. "Prior to his work at Leo Lithium and Firefinch, Marc worked for Altura Mining Ltd where he was responsible for the management and delivery of the Pre‐Feasibility Study (PFS) and DFS and the engineering, procurement, construction and commissioning for the Pilgangoora Lithium mine in the Pilbara region of Western Australia," Executive Chair Keith Coughlan comments.

----------

TT Electronics PLC - Woking, England-headquartered manufacturer of electronic components - Says its revenue growth has "accelerated" in the four months to October, as it expected. Records strong volume growth augmented by pricing and material pass-through costs. Says its order book remains "well above historic levels" across the business and provides excellent visibility for 2023. Expects to report full-year adjusted pretax in line with expectations. "Momentum across the group continues to be strong reflecting our successful positioning in structural growth markets. The team is executing well against the ongoing challenging backdrop, and we continue to expect to deliver margin improvement in the second half. While mindful of the wider macroeconomic backdrop, the continued growth in order book extends our visibility of revenues for 2023," CEO Richard Tyson comments.

----------

Ariana Resources PLC - exploration firm with interests in Turkey, Cyprus and Kosovo - Says gold production at Kiziltepe continues to be in line with guidance. Says the construction of a second gold mine at Tavsan is progressing as planned. Both are part of its "advanced" Turkish projects which are 23.5% owned by Ariana through its shareholding in Zenit Madencilik San ve Tic AS. "We are highly encouraged by the simultaneous and substantial progress being made across all advanced Turkish projects in which we hold an interest through Zenit," Managing Director Kerim Sener comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.